Press release

Humedics co‐founder Martin Stockmann awarded with Von‐ Langenbeck Prize for the development of the LiMAx test

Award ceremony at the annual conference of the German Society of Surgery

The Von‐Langenbeck Prize is an award for outstanding scientific achievements in the field of surgery. Since 1954, it has been yearly awarded by the German Society of Surgery (Deutsche Gesellschaft für Chirurgie). PD Dr. Martin Stockmann from Charité – Universitätsmedizin Berlin at the Campus Virchow Hospital, Dept. of General, Visceral and Graft Surgery, received the renowned prize for the development and clinical validation of a new technique for determining liver function in surgery – the LiMAx test – and for ten years of research in the field of liver surgery and liver regeneration. The award ceremony took place at the opening day of the 130th Congress of the German Society of Surgery in Munich. Prof. Dr. Karl‐Walter Jauch, president of the society, handed over the prize and congratulated the laureate. Stockmann said: “This prize is a great honor and pleasure for me. It is an award for more than ten years of research in the field of liver surgery and liver regeneration. I would like to take this opportunity to encourage particularly younger colleagues to engage in research. This needs superior efforts, commitment and – as the motto of this congress – passion, but it pays off.”

The award comes in a phase of the final development of the LiMAx test before regulatory product approval. In January, Humedics announced the start of a clinical phase III study. The trial with the short title 'Fast‐track LiveR' is a prospective, randomized, controlled, multi‐centric, phase III study. The main goal of this study is the early identification of low‐risk patients after partial liver resection by the LiMAx test and improvements in patient management based on test results.

Go back

About Humedics

Based in Berlin, Germany, Humedics GmbH is specialised in rapid and accurate liver function measurement using the LiMAx® test, an innovative technology for analysing exhaled air. The LiMAx® test provides physicians with a method for quantitatively assessing an individual patient’s liver function capacity within minutes. This enables physicians to select treatment strategies and follow disease progression based on up-to-date knowledge of the functional health of the liver.
 
Current applications, which have already been published in prestigious medical journals, include liver function diagnosis before and after liver transplantation, surgical planning for liver surgery (such as assessing how much liver tissue can be removed without increasing the risk of acute liver failure), and assessment of liver diseases such as fibrosis and cirrhosis.
 
At present, more than 20 studies regarding new diagnostic indications are being conducted. These include diagnosing and staging of chronic liver diseases such as non-alcoholic steatohepatitis (NASH), as well as selecting, monitoring and managing different oncology treatment options. These studies, initiated by researchers, have already provided evidence of further potential for the LiMAx® tests.
 
The LiMAx® test is in routine clinical use at more than 30 leading university hospitals in Europe. So far, more than 20,000 LiMAx® tests have been performed. The LiMAx® test is commercially available in Germany, Austria and the UK.
 
 

Contact

Humedics GmbH
Bundesallee 23
10717 Berlin
Germany

Phone: +49 30 6293 955 0
info@limaxtest.com
www.limaxtest.com